David Lucchino’s Circuitous Route To CEO Of Frequency Therapeutics
Biopharma CEO wasn’t David Lucchino’s first, second, or even third choice as a career path. Today, though, he uses elements of his diverse background to lead his second pharma startup, Frequency Therapeutics.
From Diligence To Execution — Tim Wright’s Approach To Leading MiMedx
Tim Wright shares his due diligence approach regarding MiMedx before becoming its CEO in 2019, along with how he went about implementing his 90-day business plan that would transform the company.
From Food To Pharma — Andrea Pfeifer’s Trek To Cure Alzheimer’s
CEO Andrea Pfeifer talks about why, years ago, she was convinced it was time to leave her career in the food industry and cofound AC Immune, a biopharma focused on one of the most difficult areas — Alzheimer’s disease.
Driving Diversity And Inclusion In Life Sciences
Five experts weigh in on the status of diversity and inclusion in the life sciences industry and detail actions you can take now to drive awareness and change.
Aligos Therapeutics — The Next Step Of Lawrence Blatt’s Entrepreneurial Expedition
Lawrence Blatt, Ph.D., cofounder and CEO of Aligos Therapeutics, discusses the entrepreneurial journey that took him from startup, to Big Pharma, back to startup.
Building A Digital Therapeutics Company
Brent Vaughan talks about the differences between building a biotech and building a digital therapeutics company.
The Benefits & Challenges Of Head-To-Head Trials
In Lilly’s immunology portfolio, eight different H2H clinical trials have been conducted thus far. Four of those trials were conducted in parallel with a Phase 3 trial and four were conducted after it. Although the benefits are attractive to a sponsor company, H2H trials can present some unique risks.
How One Professor Built Two Billion-Dollar Biotechs
Professor Ugur Sahin, M.D., Ph.D. never wanted to be an entrepreneur. Yet, today he’s the cofounder and CEO of BioNTech, a publicly traded German biotech aspiring to develop individualized cancer medicines. It was a surprising career path switch.
A Chat On Biosimilars With Sandoz’s U.S. President Carol Lynch
Carol Lynch, president of Sandoz U.S. and head of North America, fields biosimilars-related questions from the audience at the 2020 BIO CEO & Investor Conference.
BioEclipse Therapeutics — More Than Just A Story Of Rebranding
In 2006, Pamela Contag, Ph.D. cofounded ConcentRx, but the biopharma rebranded in 2016 to become BioEclipse Therapeutics. The CEO talks about what she learned in those 10 years on that difficult business journey
Former Biopharma CEO Develops Novel Solution For The “Valley Of Death”
I recently met a scientist who had experienced the valley of death firsthand. And rather than have her valley experience be her demise, she instead opted to develop a novel solution. This is her story.
5 Biopharma Execs Reveal Corporate Culture Best Practices
“Corporate culture will soon be the number one reason why an employee stays or leaves a company.” It’s a comment made to start off a roundtable discussion at the 2020 JPM conference, and we have the details of the discussion here.
Building GSK Oncology R&D
Axel Hoos, M.D., Ph.D., SVP oncology and R&D governance chair, provides an update and the context of GSK’s R&D strategy.
The Story Of Arrowhead Pharmaceuticals’ Adversity Odyssey
Chris Anzalone, Ph.D., CEO of Arrowhead Pharmaceuticals, discusses taking over a biopharmaceutical company shortly before the Great Recession along with other avenues of adversity faced (e.g., FDA hold on a Phase 2 trial) toward bringing this RNAi company to the brink of success.
BEYOND THE PRINTED PAGE
Some Leadership Lessons Come From Unexpected Places
Paula Ragan, Ph.D., cofounder and CEO of X4 Pharmaceuticals (subject of the November 2020 cover feature in Life Science Leader), talks about how participating in team sports can help with leadership skills later in life.
A Glimpse Into David Lucchino, Cofounder And CEO Of Frequency Therapeutics
David Lucchino, cofounder and CEO of Frequency Therapeutics, discusses how he came to meet company cofounders Robert Langer, Sc.D., and Chris Loose, Ph.D., along with transitioning from med tech to biopharma.
Looking Forward Is The Job Of Every Executive
Tim Wright, CEO of MiMedx, discusses the importance of leaders looking down the road in order to keep a business sustainable.
LIFE SCIENCE LEADER BLOGS
What Does Travel Look Like For You In 2021?
With the annual J.P. Morgan Healthcare conference going virtual in January of 2021, Rob Wright asks readers about their business travel plans for next year, and includes anonymized thoughts on posed questions from two Life Science Leader editorial advisory board members.
It’s Time We Ready Americans For The COVID-19 Long Haul
Rob Wright issues a call to action to everyone connected to the biopharmaceutical industry, recommending they begin communicating the realities of developing and distributing a COVID-19 vaccine by the end of this year.